Summit Therapeutics Receives FDA Complete Response Letter on Ivonescimab Lung Cancer Application
The FDA said progression-free survival benefit without a statistically significant overall survival gain does not support approval.
Stock reaction: SMMT shares closed down 16.5% at $11.82 on Nov. 16, from Nov. 13's close of $14.15. The S&P 500 was down 1.9% that day.

Key points
- FDA issued a Complete Response Letter on Summit's ivonescimab BLA for previously treated EGFR-mutated lung cancer
- FDA said progression-free survival benefit without a significant overall survival gain does not support approval
- Hazard ratio of 0.76 in a post-hoc analysis; primary overall survival result was not statistically significant
- Cash and investments of $629.8 million as of Sept. 30, 2026, against a $208.4 million quarterly net loss
Summit Therapeutics (Nasdaq: SMMT) said in an 8-K filed Monday that the U.S. Food and Drug Administration has issued a Complete Response Letter on its Biologics License Application for ivonescimab. The drug is proposed for patients with locally advanced or metastatic non-small cell lung cancer who have received prior EGFR tyrosine kinase inhibitor therapy. The letter says the application cannot be approved in its present form.
The press release filed with the 8-K, dated Nov. 15, 2026, says the FDA found that substantial evidence of effectiveness was not established without a statistically significant overall survival improvement. The agency said the progression-free survival benefit alone did not support a positive benefit-risk profile for approval. In the primary overall survival analysis, the combination showed a positive trend that was not statistically significant. The company also cited a post-hoc analysis of longer-term follow-up showing a hazard ratio of 0.76 in the full population, in Asian patients and in western patients.
Trial results behind the application
The application rested on HARMONi, a global, randomized, double-blind Phase III trial comparing ivonescimab plus platinum-containing chemotherapy with placebo plus the same chemotherapy. The study had two primary endpoints, progression-free survival and overall survival. The company said HARMONi met its progression-free survival endpoint and was the first global Phase III study of an immunotherapy-based regimen to show a statistically significant improvement on that measure in this setting.
The press release reported 16 patients (7.3%) discontinued ivonescimab because of treatment-related adverse events, compared with 11 patients (5.0%) who discontinued placebo. Four patients (1.8%) in the ivonescimab arm and five patients (2.3%) in the chemotherapy-alone arm died from treatment-related adverse events.
Scale of the company
At $14.15, the last close on Friday, Nov. 13, 2026, Summit's market value was about $11.32 billion, based on 799.8 million shares as of Oct. 30. The company reported a net loss of $208.4 million for the quarter ended Sept. 30, 2026, narrower than the $231.8 million loss a year earlier. Diluted loss per share was $0.26, compared with $0.31. For the 2025 fiscal year, the net loss was $1.08 billion, against $221.3 million in 2024, and diluted loss per share was $1.44, compared with $0.31.
As of Sept. 30, Summit had $150.8 million in cash and equivalents and $479.0 million in short-term investments, or $629.8 million combined. That combined balance is about three times the quarter's net loss.
What comes next
The company said it will continue its clinical development program. Summit listed several ongoing or planned studies, including HARMONi-3 and HARMONi-7 in first-line non-small cell lung cancer and HARMONi-GI3 in colorectal cancer. Chairman and Co-Chief Executive Officer Robert W. Duggan said in the press release that the company was disappointed for patients awaiting additional treatment options. He added that the company believes the HARMONi study provided the basis for a treatment option these patients needed.
The filing did not say whether Summit plans to resubmit the application or when. Ivonescimab is not approved in the United States or Europe. It received marketing authorization in China in May 2024.
Sources
Written with AI from the company's SEC filing and our market data, and checked against those sources before publishing. Our editorial standards.
More SEC filing stories
- Presidio Production to Buy Permian Oil and Gas Producers for $360 Million in Cash · FTW · Nov. 19, 2026
- IT Tech Packaging Discloses Going Concern Warning in Audit of 2025 Accounts · ITP · Nov. 20, 2026
- Americas Carmart Extends Lender Waiver and Liquidity Relief to Nov. 22 · CRMT · Nov. 19, 2026
- All In FutureTech Alliance to Buy Chairman's Little Vault for $8 Million in Stock · AIFA · Nov. 19, 2026
More on Summit Therapeutics
SMMT page →Filings, figures and price history are on the Summit Therapeutics page.